Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study

Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
Young Sup WooWon-Myong Bahk


This study was performed to investigate the efficacy and tolerability of blonanserin in schizophrenic patients who were previously treated with other antipsychotics but, due to insufficient response, were switched to blonanserin. A total of 52 patients with schizophrenia who were unresponsive to treatment with antipsychotic monotherapy or combination therapy were recruited into this 12-week, open-label, prospective, multicenter study. Patients were switched to blonanserin from their existing antipsychotics over a maximum 2-week tapering-off period. Efficacy was primarily evaluated using the 18-item Brief Psychiatric Rating Scale (BPRS). Assessments were performed at baseline, and at weeks 1, 2, 4, 8, and 12. Switching to blonanserin resulted in a significant decrease in the mean total score on the BPRS from baseline (56.8 ± 9.4) to week 12 (42.1 ± 13.8, p > 0.001). The most common adverse events were extrapyramidal symptoms (n = 12, 23.1%), insomnia (n = 10, 19.2%), and emotional arousal (n = 6, 11.5%). Overweight or obese patients (body mass index ≥ 23 kg/m2, n = 33) who switched to blonanserin exhibited significant weight loss from 75.2 ± 9.3 kg at baseline to 73.5 ± 9.2 kg at week 12 (p = 0.006). The total cholesterol (basel...Continue Reading


Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Jun 9, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hitoshi TakahashiHisashi Higuchi
Feb 8, 2007·The Journal of Clinical Psychiatry·Peter J WeidenPeter F Buckley
Mar 6, 2007·Schizophrenia Research·Marc De HertJoseph Peuskens
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Apr 3, 2010·The American Journal of Psychiatry·David M GardnerRoss J Baldessarini
Jun 14, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomoko InoueNoboru Yamaguchi
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Oct 22, 2013·Psychosomatics·Adnan AjmalLisa B Nachtigall
Oct 7, 2014·Neuropsychiatric Disease and Treatment·Taro KishiNakao Iwata
Dec 1, 2012·Acta Neuropsychiatrica·Manabu TakakiYosuke Uchitomi
Mar 10, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andrea MurruEduard Vieta
Mar 10, 2016·Harvard Review of Psychiatry·Urs HeilbronnerThomas G Schulze
Oct 25, 2016·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Yongmin KimWon-Myong Bahk
Apr 30, 2017·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Masakazu HatanoNakao Iwata
Jul 14, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gary RemingtonMichael Teehan
Feb 6, 2018·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Adarsh TripathiRashmi Shukla

Related Concepts

Combination Drug Therapy
Drug Substitution
Open Label Study

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.